Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27336187 | 0.89 | PIN1 (0.38) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL7300490 | 0.89 | HCAR2 (0.44) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL9337401 | 0.88 | GPR84 (0.46) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL2626705 | 0.86 | PIN1 (0.37) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL14959719 | 0.85 | PIN1 (0.36) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL2804373 | 0.85 | PIN1 (0.44) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL8431293 | 0.84 | KDM4E (0.43) | CYP1A2MAPK1CYP2C19 | |
| SCHEMBL8664938 | 0.84 | KDM4E (0.50) | CYP1A2MAPK1CYP2C19POLB | |
| SCHEMBL3025482 | 0.80 | GLA (0.36) | PIN1HCAR2GLAPOLBKDM5A | |
| SCHEMBL7914214 | 0.80 | PARP1 (0.40) | PIN1MAPK1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041351-B | Er (III) luminescent material containing phenanthroline, modified imidazole carboxylic acid and pyridine carboxylic acid mixed ligand and preparation method thereof | 洛阳师范学院 | 2024-04-05 | — | — | CN | claimed |
| CN-111471016-B | Synthesis method of 2-propylimidazole-4, 5-dicarboxylic acid | 湖南华腾医药有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-109824706-B | Nd (III) compound luminescent material containing modified imidazole carboxylic acid and pyridine carboxylic acid mixed ligand and preparation method thereof | 洛阳师范学院 | 2022-03-01 | — | — | CN | claimed |
| CN-108948372-B | Mn-based polycarboxylic acid coordination polymer magnetic material and preparation method thereof | 宁夏大学 | 2021-04-06 | — | — | CN | claimed |
| CN-111471016-A | Synthesis method of 2-propylimidazole-4, 5-dicarboxylic acid | 湖南华腾医药有限公司 | 2020-07-31 | — | — | CN | claimed |
| CN-104262260-B | The preparation method of high purity olmesartan medoxomill intermediate 2-propyl imidazole-4,5-dicarboxylic acid and application | HUANGGANG LUBAN PHARMACEUTICAL CO., LTD. (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-102070533-B | New method for synthesizing 4-(1-hydroxyl-1-methyl ethyl)-2-propyl imidazole-5-carboxylic acid ethyl ester | SHANGHAI SYNCORES TECHNOLOGIES INC | 2015-06-10 | — | — | CN | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| CN-104262260-A | Preparation method and application high-purity olmesartan medoxomil intermediate 2-propylimidazolyl-4,5-dicarboxylic acid | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | claimed |
| CN-103193713-A | Method for preparing 2-propylimidazole-4,5-dicarboxylic acid | CHANGZHOU BOHAIWEI MEDICAL SCIENCE & TECHNOLOGY CO LTD | 2013-07-10 | — | — | CN | claimed |
| CN-102070533-A | New method for synthesizing 4-(1-hydroxyl-1-methyl ethyl)-2-propyl imidazole-5-carboxylic acid ethyl ester | SHANGHAI SYNCORES TECHNOLOGIES INC | 2011-05-25 | — | — | CN | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| CN-1752077-A | A kind of new 2-n-propyl imidazoles-4, the preparation method of 5-dicarboxylic acid | ZHEJIANG PROV MEDICINE INST (CN) | 2006-03-29 | — | — | CN | claimed |
| CN-112778209-B | Preparation method of diacid | 宜昌东阳光长江药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110041351-B | Er (III) luminescent material containing phenanthroline, modified imidazole carboxylic acid and pyridine carboxylic acid mixed ligand and preparation method thereof | 洛阳师范学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-110041351-B | Er (III) luminescent material containing phenanthroline, modified imidazole carboxylic acid and pyridine carboxylic acid mixed ligand and preparation method thereof | 洛阳师范学院 | 2024-04-05 | — | — | CN | disclosed |
| WO-1991000277-A1 | SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | PIN1 44/4885CYP1A2 3261/4885MAPK1 2309/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | PIN1 1587/4885CYP1A2 1104/4885MAPK1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.